mProX™ Human MSLN Stable Cell Line
- Product Category:
- Membrane Protein Stable Cell Lines
- Subcategory:
To download a Certificate of Analysis, please enter a lot number in the search box below. Note: Certificate of Analysis not available for kit components.
Lot Number
Made to Order Inquiry
InquiryProduct Information
Product Properties
Protocols
Please visit our protocols page.
Customer Reviews
There are currently no Customer reviews or questions for mProX™ Human MSLN Stable Cell Line (S01YF-1023-PY279). Click the button above to contact us or submit your feedback about this product.
Skyler Smith (Verified Customer)
Patrick Liam (Creative Biolabs Scientific Support)
Casey Smith (Verified Customer)
Patrick Liam (Creative Biolabs Scientific Support)
Published Data
Fig.1 Reduction in soft agar colony formation and tumor sphere formation is observed when MSLN is knocked down.
In several stable knockdown clones, MSLN was subjected to Western blot analysis using shMSLN RNA. Representative images were captured, and soft agar colony formation of shC and shMSLN H2052 and H460 cells was quantified.
Ref: He, Xiaoqing, et al. "Mesothelin promotes epithelial-to-mesenchymal transition and tumorigenicity of human lung cancer and mesothelioma cells." Molecular cancer 16 (2017): 1-13.
Pubmed: 28288645
DOI: 10.1186/s12943-017-0633-8
Research Highlights
L, Brendan; Taka, Kazuaki. "Biology of Mesothelin and Clinical Implications: A Review of Existing Literature." World journal of oncology, 2023.
Since its discovery in 1992, mesothelin (MSLN) has been a topic of interest in the field of therapeutics. It possesses certain qualities that make it a favorable target for therapy. To start with, it is not expressed on any vital organ parenchyma. Additionally, it is differentially expressed on numerous cancer types with poor prognosis and limited systemic treatment options. Its location on the cell membrane allows for targeted therapies with large molecules. While other drug targets have been extensively studied for their therapeutic potential, the exact function and role of MSLN in cancer biology have not been fully elucidated. In this review, the existing literature on the expression patterns and cellular function of MSLN in different tumor types is examined to gain a better understanding of this peculiar molecule. However, the current understanding of MSLN is far from conclusive and there is considerable uncertainty surrounding its precise function and impact on tumor biology. It has also been observed that the expression of MSLN and its relation to prognosis varies among different tumor types. The overall mechanism by which MSLN contributes to tumor aggressiveness remains unclear. Nevertheless, it is evident that there is still much to be uncovered in this area and further research may have significant implications for the treatment of lethal malignancies.
L, Brendan; Taka, Kazuaki. "Biology of Mesothelin and Clinical Implications: A Review of Existing Literature." World journal of oncology, 2023.
Pubmed:
37869242
DOI:
10.14740/wjon1655
McCarthy, Derrick. et al. "Functional enhancement of mesothelin-targeted TRuC-T cells by a PD1-CD28 chimeric switch receptor." Cancer immunology, immunotherapy : CII, 2023.
A novel approach to cancer immunotherapy involves the use of third generation T cells expressing a fusion construct of a mesothelin (MSLN)-specific T cell receptor (TCR) and a CD28 costimulatory domain. These TRuC T cells have demonstrated potent antitumor activity against MSLN-expressing tumors in preclinical models. Additionally, they have been engineered to exhibit increased persistence and decreased potential for immune exhaustion. These promising findings suggest that TRuC T cells have the potential to be a highly effective treatment for cancer patients.
McCarthy, Derrick. et al. "Functional enhancement of mesothelin-targeted TRuC-T cells by a PD1-CD28 chimeric switch receptor." Cancer immunology, immunotherapy : CII, 2023.
Pubmed:
37848682
DOI:
10.1007/s00262-023-03556-7
